항생제의 약동학/약역학 : 기본 개념 및 임상응용

키워드

참고문헌 (45)

1. Nicolau DP, "Antibiotic kinetics and dynamics for the clinician", Med Clin North Am, 79, pp.477~495 (1995)
2. Levison ME, "Pharmacodynamics of antimicrobial agents. Bactericidal and postantibiotic effects", Infect Dis Clin North Am, 9, pp.483~495 (1995)
3. Craig WA, "Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins", Diagn Microbiol Infect Dis, 22, pp.89~96 (1995)
4. Craig WA, "Pharmacokinetic", pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, 1998, pp.26, 1~12
5. Johnson CC, "In vitro testing: correlation between bacterial susceptibility, body fluid levels, and effectiveness of antibacterial therapy In: Antibiotics in laboratory medicine", pp.813~834 (1996), Williams & Wilkins
6. Acar JF, "Disk susceptibility test In: Antibiotics in laboratory medicine" (1996), Williams & Wilkins
7. Archer GL, "Treatment and prophylaxis of bacterial infections In: Harrison's principles of internal medicine", pp.858~ (2008), McGraw-Hill
8. Turnidge JD, "The pharmacodynamics of beta-l", Clin Infect Dis, 27, pp.10~22 (1998)
9. White RL, "Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test", Antimicrob Agents Chemother, 40, pp.1914~1918 (1996)
10. Manduru M, "Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method", Antimicrob Agents Chemother, 41, pp.2527~2532 (1997)
11. MacKenzie FM, "The post-antibiotic effect", J Antimicrob Chemother, 32, pp.519~537 (1993)
12. Zhanel GG, "Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides", Clin Pharmacokinet, 27, pp.377~392 (1994)
13. Majcherczyk PA, "The Issue of the true postantibiotic effect", J Antimicrob Chemother, 37, pp.188~190 (1996)
14. Lee DG, "Postantibiotic effect of ceftriaxone and amikacin on Klebsiella pneumoniae ATCC 43816", Kor J Clin Pharmacol Ther, 7, pp.49~58 (1999)
15. Fantin B, "Factors affecting the duration of in-vivo postantibiotic effect for aminoglycosides against gram- negative bacilli", J Antimicrob Chemother, 27, pp.829~836 (1991)
16. den Hollander JG, "Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model", Antimicrob Agents Chemother, 40, pp.784~786 (1996)
17. Craig WA, "Pharmacodynamics of antimicrobials: general concepts and applications In: Antimicrobial pharmacodynamics in theory and clinical practice", pp.1~19 (2007), Informa healthcare
18. Andes D, "Animal model pharmacokinetics and pharmacodynamics: a critical review", Int J Antimicrob Agents, 19, pp.261~268 (2002)
19. Mouton JW, "Tissue concentrations: do we ever learn", J Antimicrob Chemother, 61, pp.235~237 (2008)
20. Liu P, "Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations", Int J Antimicrob Agents, 19, pp.285~290 (2002)
21. Ambrose PG, "Clinical pharmacodynamics of quinolones", Infect Dis Clin Notrth Am, 17, pp.529~543 (2002)
22. Craig WA, "Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections", J Antimicrob Chemother, 27, pp.29~40 (1991)
23. Craig WA, "Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid", Infect Dis Clin North Am, 17, pp.479~501 (2003)
24. Hyatt JM, "The importance of pharmacokinetic", pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents, 1995, pp.28, 143~160
25. Lode H, "Pharmacodynamics of fluoroquinolone", Clin Infect Dis, 27, pp.33~39 (1998)
26. Safdar N, "In vivo pharmacodynamic activity of daptomycin", Antimicrob Agents Chemother, 48, pp.63~68 (2004)
27. Schentag JJ, "Pharmacodynamic interactions of antibiotics alone and in combination", Clin Infect Dis, 27, pp.40~46 (1998)
28. Vogelman B, "Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model", J Infect Dis, 158, pp.831~847 (1988)
29. Maglio D, "Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides", Infect Dis Clin North Am, 17, pp.563~577 (2003)
30. Lee DG, "Inoculum effect of daptomycin, linezolid, vancomycin, and ceftobiprole with Staphylococcus aureus and Streptococcus pneumoniae in neutropenic mice at 105 and 107 CFU in opposite thighs", 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2007)
31. Leggett JE, "Comparative antibiotic dose-effect relations at several dosing intervals in murine penumonitis and thigh-infection models", J Infect Dis, 159, pp.281~292 (1989)
32. Criag WA, "Antimicrobial resistance issues of the future", Diagn Microbiol Infect Dis, 25, pp.213~217 (1996)
33. Mouton JW, "Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations", J Antimicrob Chemother, 38, pp.5~15 (1996)
34. Turnidge JD, "Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime", Diagn Microbiol Infect Dis, 22, pp.57~69 (1995)
35. Moore RD, "Clincal response to aminoglycoside therapy: importance of peak concentration to minimal inhibitory concentrations", J Infect Dis, 155, pp.93~99 (1987)
36. Gilbert DN, "Once-daily aminoglycoside therapy", Antimicrob Agents Chemother, 35, pp.399~405 (1991)
37. Nicolau DP, "Experience with a once-daily aminoglycoside program administered to 2,184 adult patients", Antimicrob Agents Chemother, 39, pp.650~655 (1995)
38. Hatala R, "Once-daily aminoglycoside dosing in immunocompetent adults:a meta-analysis", Ann Intern Med, 124, pp.717~725 (1996)
39. Hatala R, "Single daily dosing of aminoglycosides in immunocompromised adults: a systemic review", Clin Infect Dis, 24, pp.810~815 (1997)
40. Prins JM, "Once versus thrice daily gentamicin in patients with serious infections", Lancet, 341, pp.335~339 (1993)
41. Ambrose PG, "Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore", Clin Infect Dis, 44, pp.79~86 (2007)
42. Lee H, "Clinical relevance of pK and pD in anti- infective agents", Infect Chemother, 40(1), pp.S35~S39 (2008)
43. Heffelfinger JD, "Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group", Arch Intern Med, 160, pp.1399~1408 (2000)
44. Anon JB, "Sinus And Allergy Health Partnership: Antimicrobial treatment guidelines for acute bacterial rhinosinusitis", Otolaryngol Head Neck Surg, 130(1), pp.1~45 (2004)
45. Andes D, "Understanding pharmacokinetics and pharmacodynamics: application to the antimicrobial formulary decision process In: Antibiotic optimization: concepts and strategies in clinical practice", pp.65~80 (2005), Marcel Dekker